Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

61.96 -0.11 (-0.18%)
Streaming Delayed Price Updated: 2:53 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 770,513
Open 62.04
Bid (Size) 61.95 (200)
Ask (Size) 61.96 (200)
Prev. Close 62.07
Today's Range 61.49 - 62.28
52wk Range 34.08 - 62.45
Shares Outstanding 388,132,400
Dividend Yield 1.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
If You Invested $1000 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annualized basis producing an average annual return of 40.75%. Currently, Royalty Pharma has a market... 
Via Benzinga
News headline image
Here’s How Much You Would Have Made Owning Royalty Pharma Stock In The Last 10 Years ↗
Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annualized basis producing an average annual return of 39.56%. Currently, Royalty Pharma has a market... 
Via Benzinga

Performance

YTD
+59.4%
+59.4%
1 Month
+5.5%
+5.5%
3 Month
+15.0%
+15.0%
6 Month
+36.5%
+36.5%
1 Year
+72.2%
+72.2%

More News

Read More
Royalty Pharma (NASDAQ:RPRX) Hits Perfect Technical Rating with Breakout Setup ↗
Via Chartmill
News headline image
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Royalty Pharma (NASDAQ:RPRX) Beats Q2 Revenue Estimates, Raises Full-Year Guidance ↗
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
Via Chartmill
News headline image
Royalty Pharma Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Royalty Pharma reports second quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma declares third quarter 2026 dividend
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
Topics Supply Chain
News headline image
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Royalty Pharma to present at upcoming investor conferences
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Royalty Pharma reports first quarter 2026 results
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 61.96
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 08/26/26 02:53 PM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 24.05B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 24B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.